pipette
ENEnglish

Active immunotherapy against IL-1β restores tissue repair under chronic inflammation

Pablo Cordero Alvarado, Natalie Kley, Eleanor L. P. Caston, Alejandra Suarez‐Arnedo, Shamitha Shetty, Sophia Zhang, Tatiana Segura, Joel H. Collier

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Chronic inflammation driven by sustained interleukin-1 beta (IL-1β) signaling disrupts the resolution phase of tissue repair by orchestrating dysregulated immune activity. As a key upstream mediator, IL-1β prolongs the activation of pro-inflammatory myeloid cells and establishes an environment that prevents the transition to tissue repair. Here, we developed an active immunotherapy against IL-1β using the self-assembling peptide nanofiber Coil29, which elicits robust and specific IL-1β-targeted immune responses in both wild-type and diabetic mice, without inducing systemic immunosuppression. In a chronic wound model, the therapy accelerated re-epithelialization and enhanced overall tissue regeneration, outperforming anti-IL-1β monoclonal antibodies. This therapy suppressed macrophage activity, promoted their M2-like polarization, enhanced pro-healing cytokine secretion and enriched the injury site with anti-IL-1β antibodies. In vitro, we found that antibodies from immunized mice reprogrammed M1 macrophages toward an M2-like phenotype, suggesting that antibody-mediated modulation of IL-1β activity may drive the enhanced wound re-epithelization seen in immunized animals. Altogether, these findings highlight a targeted, regenerative therapy for the healing of chronic wounds.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 4 de noviembre. Proceedings of the National Academy of Sciences. Revista con revisión por pares.

DOI: 10.1073/pnas.2609135123